FLGT News and Press, Fulgent Genetics Inc. From 09/18/21

There were a lot of companies that jumped to action last year in the fight against the SARS-CoV-2 virus. Videoconferencing, e-commerce, delivery apps, drug development and diagnostics all prospered. In that latter category, one company proved it has a business model to succeed long afte...

A once-a-century pandemic has created a tough task for management teams trying to forecast the future. A wave of COVID-19 can shut down businesses, ramp up online commerce, and generally upend any well-meaning forecast. That's what has happened with Fulgent Genetics (NASDAQ: F...

It has been said that the stock market may be the only place where buyers get cold feet when the prices drop. It's funny to think about. Shouldn't you want to buy stocks when they are cheaper? We asked three Fool contributors what stocks they think are cheap right now. They came up ...

The dream of truly being in a post-Covid-19 world is finally beginning to fade away with the rise of the Delta variant. The future appears more and more set on “management of an endemic pathogen” than the eradication of this foe. It will always find somewhere to hide out and mut...

Shares of coronavirus testing company Fulgent Genetics (NASDAQ: FLGT) are down 16.2% to $91.98 apiece as of 10:30 a.m. EDT. During the second quarter of 2021, reported yesterday, the company's revenue grew by a stunning 790% year over year to $153.6 million. Simultaneously...

Fulgent Genetics reported earnings recently, on August 9th, 2021. Fulgent dropped nearly 15% after the earnings report, likely due to misses on both revenue and EPS estimates. Despite missing estimates, Fulgent had an strong quarter, showing strong growth along with other announce...

The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Fulgent Genetics, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Fulgent Genetics, Inc. Common Stock (NASDAQ: FLGT) Q2 2021 Earnings Call Aug 09, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. Common Stock (FLGT) Q2 2021 Earn...

Fulgent Genetics, Inc. (FLGT) Q2 2021 Earnings Conference Call August 09, 2021 04:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Larry Weiss - Chief Medical Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Of...

Revenue grows 790% year over year to $153.6 million Core Revenue grows 296% year over year to $25.7 million Announces acquisition of CSI Laboratories Announces commercial agreement with Helio Health through strategic investment Announces incremental controlling investm...